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Abstract
Background: Long-term biodistribution of nanomaterials used in medicine is largely unknown. This is the case for
alum, the most widely used vaccine adjuvant, which is a nanocrystalline compound spontaneously forming micron/
submicron-sized agglomerates. Although generally well tolerated, alum is occasionally detected within monocyte-
lineage cells long after immunization in presumably susceptible individuals with systemic/neurologic manifestations
or autoimmune (inflammatory) syndrome induced by adjuvants (ASIA).
Methods: On the grounds of preliminary investigations in 252 patients with alum-associated ASIA showing both a
selective increase of circulating CCL2, the major monocyte chemoattractant, and a variation in the CCL2 gene, we
designed mouse experiments to assess biodistribution of vaccine-derived aluminum and of alum-particle fluorescent
surrogates injected in muscle. Aluminum was detected in tissues by Morin stain and particle induced X-ray emission)
(PIXE) Both 500 nm fluorescent latex beads and vaccine alum agglomerates-sized nanohybrids (Al-Rho) were used.
Results: Intramuscular injection of alum-containing vaccine was associated with the appearance of aluminum deposits
in distant organs, such as spleen and brain where they were still detected one year after injection. Both fluorescent
materials injected into muscle translocated to draining lymph nodes (DLNs) and thereafter were detected associated
with phagocytes in blood and spleen. Particles linearly accumulated in the brain up to the six-month endpoint; they
were first found in perivascular CD11b+ cells and then in microglia and other neural cells. DLN ablation dramatically
reduced the biodistribution. Cerebral translocation was not observed after direct intravenous injection, but significantly
increased in mice with chronically altered blood-brain-barrier. Loss/gain-of-function experiments consistently
implicated CCL2 in systemic diffusion of Al-Rho particles captured by monocyte-lineage cells and in their subsequent
neurodelivery. Stereotactic particle injection pointed out brain retention as a factor of progressive particle
accumulation.
Conclusion: Nanomaterials can be transported by monocyte-lineage cells to DLNs, blood and spleen, and, similarly to
HIV, may use CCL2-dependent mechanisms to penetrate the brain. This occurs at a very low rate in normal conditions
explaining good overall tolerance of alum despite its strong neurotoxic potential. However, continuously escalating
doses of this poorly biodegradable adjuvant in the population may become insidiously unsafe, especially in the case of
overimmunization or immature/altered blood brain barrier or high constitutive CCL-2 production.
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Background
Nanomaterials have various innovative medical applica-
tions including drug and gene delivery, imaging contrast
fluids, topical antimicrobials, surgery tools and vaccines
[1]. Due to the growing number of novel compounds
and formulations, data on their specific biodistribution,
persistence and toxicity are generally lacking [1], and
clarification regarding how the body handles small parti-
cles, especially those which interact with immune cells
[2], is urgently needed. Once defined, these basic mecha-
nisms which govern host-particle interactions should be
integrated with specific properties of nanomaterials (size,
shape, surface, and solubility) to enable predictions of
their beneficial or adverse effects.
The use of nanomaterials in humans is not as contem-
porary as is recently portrayed. For decades, alum, a nano-
crystalline compound formed of aluminum oxyhydroxide,
has been the most commonly used adjuvant in vaccines.
The mechanism by which it stimulates the immune re-
sponse is incompletely understood [3]. While alum is
generally well tolerated, it is occasionally reported as the
cause of disabling health problems in individuals with ill-
defined susceptibility factors [4-6]. Clinical manifestations
attributed to alum are paradigmatic of the so-called auto-
immune/inflammatory syndrome induced by adjuvants
(ASIA), a syndrome also observed in patients exposed to
silicone gel [7]. They include delayed onset of diffuse
myalgia [4], chronic fatigue [8] and stereotyped cognitive
dysfunction [9]. The persistence of alum-loaded macro-
phages is typically detected at sites of previous injections
(up to >12 years later), resulting in a specific granuloma
called macrophagic myofasciitis or MMF [4]. Although
the biopersistence of adjuvants is a priori undesirable, the
exact significance of this remains the subject of some debate
since the biodistribution of slowly biodegradable particles
following injection into muscle is currently unknown.
There appears to be a fine balance between the efficacy
of alum adjuvant and its potential toxicity, and there is
good evidence that these may be one and the same effect
[3]. Both the efficacy and the potential toxicity of alum will
be influenced by whether the bioactive nanomaterial re-
mains localized at injection points or rather scatters and
accumulates in distant organs and tissues. A reference
study based on isotopic 26Al showed poor (6%) 26Al clea-
rance in the urine at the day 28 (d28) endpoint after i.m.
injection of isotopic alum to rabbits, and detected 26Al, in
an unknown form, in lymph nodes, spleen, liver, and brain
[10]. Aluminum oxyhydroxide is composed of micron/
submicron-sized aggregates of nano-sized (about 13 nm)
particles and these aggregates were initially believed to re-
main extracellular until their complete solubilization in
interstitial fluids [10]. We now know that quite the reverse
is the case and that antigen presenting cells (APCs) avidly
take up alum particles [11], and, in so doing, become
long-lived cells [12] and impede alum solubilization
[4,13,14]. Inflammatory monocytes (MOs) are attracted
into muscle by danger signals through a monocyte chemo-
attractant protein-1 (MCP-1)/chemokine (C-C motif) lig-
and 2 (CCL2) driven-mechanism, becoming macrophages
(MPs) and MO-derived dendritic cells (DCs), before mi-
grating to the draining lymph nodes (DLNs) [15]. One
function of migratory DCs is to transfer antigenic material
to a large network of distant resident APCs [16]. More-
over, injections of alum alone induce significant changes
linked to activation of the innate immune system in dis-
tant organs [17,18]. Therefore, we examined whether
nanomaterials injected into muscle could translocate to
distant organs as part of a general mechanism linked to
phagocytosis and CCL2/MCP-1 signaling.
Methods
Mice models
All animal experiments were conducted in accordance
with the European guidelines for animal care. To facili-
tate mechanistic investigation of particle biodistribution,
mice of the B57/B6 genetic background, that are used to
generate genetically-manipulated models, were preferred
to more toxic-sensitive mouse strains. Male eight- to
ten-week-old C57BL/6, mdx (with leaky blood brain
barrier (BBB)), CX3CR1GFP/+ (with GFP reporter gene
insertion allowing visualization of microglia), and CCL2−/−
mice were used (Jackson, West Grove, PA, USA). Mice
were protected from Al-containing materials, fed with
manufactured animal food and water ad libitum, and
exposed to 12:12 light/dark cycles. Experiments using
fluorescent particles were extremely labor intensive and
expensive to perform. All of them were done in triplicate.
Homogeneity of results made it unnecessary to use more
than three mice per point.
Alum administration
The dose of alum-containing vaccine administered to
mice was calibrated to mimic the mean number of doses
received by MMF patients. One dose of commercially
available anti-hepatitis B vaccine contains 0.5 mg Al
according to the product data sheet. Based on an average
of human body weight of 60 kg (most patients being
women), the amount received for each immunization is
8.33 μg/kg. The allometric conversion from human to
mouse (FDA Guidance 5541) gives a final amount of ap-
proximately 100 μg/kg. A dose of 36 μL vaccine, which
corresponds to 18 μg Al, was injected to mimic the cu-
mulative effect induced by 5.2 human doses to 35 g mice
(the mean weight at the d180 midtime of brain analysis).
This dose represents an equivalent 6.8 human doses in
the youngest animal (27 g body weight, 11 weeks of age
at sacrifice) and 4.3 in the oldest one (42 g at 62 weeks).
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Furnace atomic absorption spectrometry
Al concentrations were determined in whole tibialis an-
terior (TA) muscles and brains dried at 37°C and
digested with concentrated HNO3 (14 mol/L). Digests
were allowed to cool before dilution to 10% HNO3 with
ultra-pure water. The total aluminum in each digest was
measured by transversely heated graphite atomizer
graphite furnace atomic absorption spectrometry (TH
GFAAS) and results were expressed as Al mg/g tissue
dry weight.
PIXE
As in normal conditions Al may be detected with marked
interindividual variations in tissues, de novo incorporation
of aluminum in too low doses does not cause easily de-
tectable changes when global conventional approaches are
used [10]. Here we used particle induced X-ray emission
(PIXE), a procedure analyzing radiation emitted from the
interaction of a proton beam with the matter [19], to de-
tect areas enclosing small Al spots. Sections (20 μm-thick)
carefully protected from environmental Al were mounted
on fresh formvar films, kept in the cryostat for 6 hours
and stored under Al-free silica gel. Mineral and metal ions
were detected using the nuclear microprobe of the Centre
d’Etudes Nucléaires de Bordeaux-Gradignan. A 1 MeV
proton beam focused down to a 2 μm spot was randomly
scanned over multiple 500 × 500 μm fields of tissue sec-
tions. In the case of an Al signal, a re-test of 100 × 100
μm areas of interest was performed. PIXE and Rutherford
backscattering spectrometry analyses were employed si-
multaneously and quantitative results were computed, as
previously described [19]. Al spots were considered eli-
gible on three criteria: a size of more than 3 pixels (that is,
above the background noise), a depot not colocalized with
Si, and a depot surrounded by a rounded halo of de-
creased intensity (both characteristics limiting confusion
with contamination by external dust overcoming the pro-
tection procedures).
Synthesis of Al-Rho particles
Gadolinium oxide nanohybrids with Al(OH)3 coating were
obtained in three steps: (i) gadolinium oxide nanoparticles
were first synthesized; (ii) polysiloxane shell growth was
then induced by hydrolysis-condensation of convenient
silane precursors in the presence of the nanoparticles;
and (iii) the nanohybrids were coated by the addition of
aluminum nitrate and soda in stoichiometric conditions.
Chemicals
Gadolinium chloride hexahydrate ((GdCl3, 6H2O]) 99.99%),
sodium hydroxide (NaOH, 99.99%), tetraethyl orthosilicate
(Si(OC2H5)4, TEOS, 98%), (3-aminopropyl) triethoxysilane
(H2N(CH2)3-Si(OC2H5)3, APTES, 99%), triethylamine
(TEA, 99.5%), rhodamine B isothiocyanate (RBITC),
aluminium nitrate nonahydrate (Al(NO3)3.9H2O, ACS re-
agent ≥ 98%) and dimethyl sulfoxide (DMSO, 99.5%) were
purchased from Sigma-Aldrich (St Louis, MO, USA). Di-
ethylene glycol (DEG, 99%) was purchased from SDS
Carlo Erba, Val de Reuil (France).
Preparation of gadolinium oxide core
A first solution was prepared by dissolving GdCl3,
6H2O (0.56 g) in 50 mL DEG at room temperature. A
second solution was prepared by adding a NaOH solu-
tion (0.49 mL, 10 M) in 50 mL DEG. The second solu-
tion was progressively added to the first one, at room
temperature, for 15 hours. A transparent colloid of
gadolinium oxide nanoparticles in DEG was obtained.
Encapsulation of Gd2O3 cores by polysiloxane shell
A total of 105 μL of APTES and 67 μL of TEOS was
added to 100 mL of the gadolinium oxide nanoparticle so-
lution under stirring at 40°C. A total of 5 μL of APTES
was previously coupled to 1 mg RBITC in DMSO (1 mL)
used as solvent and then added to the colloidal solution.
After 1 hour, 1,913 μL of a DEG solution (0.1 M of TEA,
10 M of water) was added. The whole coating procedure
was repeated three more times (with no more addition of
RBITC), every 24 hours. The final mixture was stirred for
48 hours at 40°C. The obtained solution could be stored at
room temperature for weeks without alteration.
Coating of fluorescent nanohybrids with a Al(OH)3 shell
A total of 2.5 mL of the colloidal solution was diluted by
2 to obtain a 5 mL solution in DEG. A total of 75 mg
of aluminum nitrate nonahydrate was dissolved in 10 mL
of water before addition to the colloidal solution. The
resulting mixture was stirred for 5 minutes and 4 mL of a
soda solution (0.2 M) was added before stirring for 1 hour.
Purification
Purification of Al-Rho was performed by tangential filtra-
tion through Vivaspin filtration membranes (MWCO = 10
kDa) purchased from Sartorius Stedim Biotech (Aubagne,
France). The colloidal solution was introduced into 20 mL
Vivaspin tubes and centrifuged at 4,100 rpm. This step
was repeated several times, by filling the tubes with water
and centrifuging again, until the desired purification rate
was reached (≥100). The purified colloidal solution was
freeze dried for storage in five pillboxes, using a Christ
Alpha 1–2 lyophilisator. The compound contained 4 μg
Al per μL of Al-Rho suspension. Control transmission
electron microscopy showed non-fibrous particles about
10 nm in size, typical of aluminum hydroxyde (traditional
precipated alum). Similarly to vaccine alum, they formed
agglomerates of submicronic/micronic size. The immuno-
logical properties of such traditional alum-protein precipi-
tates are quite similar to those of the reference adjuvant
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approved by the FDA (Al oxyhydroxyde: AlhydrogelW,
Invivogen, Toulouse France) and differ from other formu-
lations not licensed for human use (18).
Peripheral injections of fluorescent nanomaterials
Two types of fluorescent nanomaterials were used: ex-
ploratory polychromatic fluorescent latex beads (FLBs)
(500 nm fluorospheres, Polysciences, Warrington, PA,
USA) and confirmatory Al-Rho nanohybrids cons-
tructed with a rhodamine containing core and an Al
(OH)3 shell. FLBs were used first because they offer sev-
eral characteristics that facilitate their detection in tis-
sues, including strong fluorescence, spheric appearance
and homogeneous size. This allowed us to get a clear
picture of what was happening in terms of biodis-
tribution of these avidly phagocytosed particles. Al Rho
particles were less fluorescent and more heterogeneous
in shape and size than FLBs but better represented alum
adjuvant surrogates. Almost all biodistribution experi-
ments performed with FLBs in wild type mice were also
done with Al-Rho. In contrast, FLBs and Al Rho
were differentially used in mutated/genetically-modified
mice: FLBs were preferred to study particle biodis-
tribution in mdx mice with BBB alterations and when
the GFP marker was used (that is, CX3CR1GFP/+ mice
with fluorescent microglia, GFP + BMT studies); Al-Rho
particles were preferred in gain/loss of CCL2/MCP-1
function studies designed on the basis of preliminary re-
sults on the CCL2 status of alum-intolerant humans.
FLB suspension diluted at 1:1 in PBS contained 1.8 ×
1011 particles per mL. A total volume of 40 μL (20 μL
in each TA muscle) was injected, corresponding to a
total amount of 7.2 × 109 particles. The same volume of
Al-Rho suspension was injected in TA muscles. PBS-
injected mice were used as controls. Tissues, including
popliteal and inguinal DLNs, spleen, brain and blood,
were collected at various time points post injection.
Three mice were included per group at each time point
for both injected materials and their controls. Other ad-
ministration routes were compared to the standard i.m.
injection, including s.c. injection of 20 μL FLBs in each
hindlimb, and i.v. injection of 40 μL FLBs in the tail
vein.
Stereotactic cerebral injections
Mice were anaesthetized with ketamine and xylazine. Al-
Rho suspension (0.5 μL) was stereotactically injected in the
striatum using a 1 μL Hamilton syringe. Biodistribution of
i.c. injected Al-Rho to cervical DLNs, assessed by serial
sectioning of the whole cervical region, and spleen, was
compared to biodistribution to the popliteal DLN and
spleen of the same amount of Al-Rho injected in the TA
muscle.
Pharmacological and physical migration blockade
The prostaglandin analog BW245C, an agonist of the
PGD2 receptor, was used to inhibit APC migration as pre-
viously reported [20]. Since BW245C is active for two days
after injection, BW245C (100 nM, Cat.no.12050, Cayman
Chemical, Ann Arbor, MI, USA) was injected twice in the
TA muscle: it was first co-injected with FLBs at d0 and a
second time alone at d2, and DLNs were removed for
examination at d4. Untreated FLB-injected mice were
used as controls. In another set of experiments DLNs were
surgically ablated and mice immediately injected with
FLBs in the TA muscle.
Loss and gain of CCL2 function experiments
Exploratory analyses performed in MMF patients with
ASIA [see Additional file 1: supplementary information
section] yielded a CCL2 signal in the form of: (1) a se-
lective increase of CCL2 in the serum of MMF patients
compared to healthy controls; and (2) a given haplotype
in the CCL2 gene tending to be more frequent in MMF
patients than in the general population. These results
led us to use mouse models to explore the role of CCL2
in the biodisposition of particulate materials. Loss of
CCL2 function studies were done using CCL2−/− mice
injected i.m. with 40 μL Al-Rho. Gain of CCL2 function
experiments consisted first of i.m. co-injection of 10 μL
murine rCCL2 (100 μg/ml; R&D, Minneapolis, MN,
USA) with 40 μL Al-Rho. DLNs were removed at d4,
spleen, brain and blood at d21. In other experiments
murine rCCL2 was infused into the brain through a
catheter stereotactically inserted into the striatum at d7
post-Al-Rho, fed by a subcutaneously implanted osmotic
micropump fixed into the neck (0.25 μL/hour Alzet
brain infusion kit, Charles River, L’Arbresle, France).
rCCL2 was infused for 14 days (diffusion rate 180 pg/day),
with or without rCCL2 i.m. injection concurrent with
Al-Rho injection. At d21 post Al-Rho injection, ani-
mals were sacrificed, and blood and tissues were col-
lected. For controls, osmotic pumps filled with PBS
were used.
Tissue preparation and particle counting
Mice under terminal anesthesia were transcardially per-
fused with PBS followed by ice-cold 4% paraformalde-
hyde (PFA) in 0.1 M phosphate buffer. Tissues and
organs were removed, post-fixed in PFA for 4 hours at
4°C, immersed overnight at 4°C in a 30% sucrose solu-
tion, and quickly frozen. Whole brains were serially cut
into coronal cryosections of 40 μm, spleen and muscle
into 20 μm, and DLNs into 10 μm, and stored at −20°C
until particle counting or treatment. Brain sections were
successively deposited on 10 different SuperfrostW slides
in order to obtain 10 identical series, thus allowing de-
termination of total particle content by multiplying by
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10 the number of particles found in one series. A similar
approach was used for DLNs and spleen. Blood was col-
lected by heart puncture and 100 μL were smeared for
particle counting.
Immunohistochemistry and Morin staining
Immunostaining was done using commercial primary
antibodies routinely used in the lab, raised against CD11b
(1/200, AbD Serotec, Oxford, UK), F4/80 (1/50, AbCam,
Cambridge, UK), GFAP (1/200, DakoCytomation, Trappes,
France), vimentin (1/500 DakoCytomation), collagen
IV (1/100 Millipore, Temecula, CA, USA), NG2 (1/200,
Millipore, Molsheim, France), MAP2 (1/100, Sigma-
Aldrich, Lyon, France), and IL1β (1/100, AbCam,
Paris, France) or nonspecific mouse IgG (Jackson
ImmunoResearch, Suffolk, UK). Then, biotinylated
anti-rat and anti-rabbit antibodies (1/200, Vector Labora-
tories, Paris, France) were used accordingly and were re-
vealed using Alexa fluor 488-conjugated streptavidin
(1/200 Invitrogen, Cergy-Pontoise, France). Neuron la-
beling was done using NeuroTraceW blue fluorescent
Nissl Stain according to the manufacturer” instructions
(Invitrogen). Al was stained with Morin (M4008-2 G,
Sigma-Aldrich) used as 0.2 g dissolved in a solution
consisting of 0.5% acetic acid in 85% ethanol [21]. Forma-
tion of a fluorescent complex with Al was detected
under a 420 nm excitation wavelength as an intense
green fluorescence with a characteristic 520 nm emis-
sion. Notably, nanohybrids (Gd2O3) core encapsulated
by polysiloxane shell were not positively stained by
Figure 1 Aluminum deposits in tissues following injection of alum-containing vaccine in the TA muscle. a) Granuloma composed of PAS+
cells is formed in the injected muscle envelope; b) PIXE mapping shows muscle Al deposits in pseudocolors, with confirmatory Al emission
spectrum (d21); c) Section of spleen tissue (left panel) displays the large 500 × 500 μm and restricted 100 × 100 μm protonized fields
corresponding to the PIXE maps (middle and right panel, respectively) enclosing eligible Al spots (d21); d) Section of brain tissue (left left panel)
displays the restricted 100 × 100 μm protonized field corresponding to the PIXE map (middle panel) enclosing eligible Al spot (d21); the number
of fields containing one or more Al spots was increased at all tested time points compared to unvaccinated (right panel) mice. (bars: 100 μm). d,
day; PIXE, particle induced X-ray emission, TA tibialis anterior.
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Figure 2 FLB translocation in DLN following injection in TA muscle. a) Marked translocation of FLBs in parafollicular areas of popliteal DLNs
(d4); b) Flow cytometry showing that most FLB-loaded cells extracted from DLN express CD11c at either an intermediate or strong level (d4);
c) Immunocytochemistry on CD11b+ cells extracted from DLNs were usually Gr1+/Ly6C+, especially when they had ingested a few particles (left),
whereas heavily loaded ones were often Gr1-/Ly6C- (right); d) The number of FLB-loaded cells peaked at d4 post-injection in both popliteal and
inguinal DLNs; e) The migration inhibitor BW245C co-injected with FLBs in muscle markedly decreased the number of FLB-loaded cells detected
in DLNs at d4 post-injection. The effect was more pronounced in the downstream inguinal DLN; f) The migration inhibitor BW245C co-injected
with FLBs in muscle markedly decreased the number of FLB-loaded cells detected in DLNs at d4 post-injection. The effect was more pronounced
in the downstream inguinal DLN; (histograms: n = 3 per group, mean + SD, * P <0.05, ** P <0.01, *** P <0.005; bars: 100 μm [a]; 5 μm [c]). d, day;
DLNs, draining lymph nodes; FLBs, fluorescent latex beads; TA, tibialis anterior.
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Morin. In contrast, when coated with Al(OH)3, these par-
ticles were strongly positive for Morin. Fluorescence mi-
croscopy and spectral analyses were done using Carl Zeiss
light and confocal microscopes.
Cell isolation from blood and tissues and flow cytometry
For blood cell immunophenotyping, 100 μL blood was
treated with ethylenediaminetetraacetic acid (EDTA) and
stained with fluorescein isothiocyanate (FITC)-conjugated
antibodies. Erythrocytes were lysed using hypotonic lysis
solution, and then cells were washed with (D)MEM and
sorted using a MoFlo cell sorter (Beckman Coulter,
Villepinte, France). Cells were extracted from tissues of
exsanguinated mice perfused with PBS. Tissues were re-
moved and freshly dissociated in (D)MEM. DLNs and
spleen were dissociated in (D)MEM containing 0.2%
collagenase-B (Roche Diagnostics, Meylan, France)
and 0.2% trypsine-EDTA at 37°C for 45 minutes twice.
Brain tissue was dissociated in 1% Trypsin-HBSS
(Thermo Scientific HyClone, South Logan, UK) containing
100 U/mL DNase (Roche Diagnostics). Cell suspensions
were filtered and counted. CD45+ or CD11b+ cells were
isolated using magnetic cell sorting (MACS, Miltenyi
Biotec, Paris, France) and stained with one of the fol-
lowing antibodies and their isotypes: FITC-conjugated
anti-CD11b, FITC–conjugated anti–Ly-6C (GR1), FITC–
conjugated anti-CD11c (BD-Pharmingen Bioscience, San
Diego, CA, USA). Cells were sorted using a cell sorter. Pop-
ulations presenting >90% purity were used. Sorted cells
were cytospinned and stained with Hoechst-33342 for nu-
cleus. Particle loaded cells were counted under a fluores-
cence microscope.
Bone marrow transplantation experiments
GFP+ bone marrow (BM) cells were obtained by flushing
the femurs of adult CAG-GFP mice and were injected
Figure 3 FLB biodistribution in spleen and blood following injection in TA muscle. a) The number of FLB-loaded cells peaked at d21 in
spleen; b) In spleen, FLBs were detected in CD11b+ cells as assessed by immunohistochemistry (left) or after cell sorting (right); c) On blood
smears, most FLBs were cell-associated from d4 and peaked at d21 post injection; circulating FLB-loaded cells were still detected at d90 endpoint;
d) Circulating FLB-loaded cells were CD11b+ (d21); e,f) GR1/Ly6C immunophenotyping of CD11b+ cells that have ingested FLBs. Most are Gr1+
/Ly6C+ both in DLNs at d4 (a) and in spleen at d21 (b). (histograms n = 3 per group, mean ± SD, * P <0.05, ** P <0.01, *** P <0.005; bars: 5 μm).
d, day; FLB, fluorescent latex beads; n, number; TA, tibialis anterior.
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retroorbitally (1 × 107 cells per mouse) to four-week-old
C57BL/6 mice, as previously described [15]. Recipient
mice were irradiated at 9.0 Gy on d1 before transplant-
ation, and were treated with 10 mg/kg/day ciprofloxacin
for 10 days. Blood chimerism of >90% was controlled at
three to four weeks post-transplantation.
Statistical analyses
All experimental values are presented as means and stan-
dard deviation except when indicated. Statistical analyses
used unpaired Student’s t-test (genotypes); P <0.05 was con-
sidered significant.
Results
Intramuscular alum-containing vaccine injection in mouse
induces Al deposition in distant tissues
Alum-containing vaccine (36 μL corresponding to 18 μg
Al) was first injected in the TA muscles of C57Bl6 mice.
It induced an acute inflammatory reaction which stabi-
lized after d4 in the form of collections of typical alum-
loaded MPs with large hematoxylin+ and Periodic Acid
Schiff+ cytoplasm in muscle envelopes (Figure 1a). In
parallel, the local Al tissue concentration determined by
atomic absorption spectrometry decreased by 50% from
injection to d4 and then remained stable until d21
Figure 4 Brain translocation of FLBs following injection in TA. a) Cerebral translocation of FLBs was delayed but relentless until the d90
endpoint in C57 mice and the d180 endpoint in the CX3CR1GFP/+ mouse; b) Unstained section of the brainstem in a C57 mouse at d21 post-
injection showing FLBs mostly distributed in the subpial region; c) FLBs distribution in the brain: areas enriched in FLBs were reported on semi-
serial rostro-caudal sections of mouse brain stained by Cresyl violet (A to G), using dots of different colors according to the considered time point
(d21 to d365) after i.m. injection. Report was done regardless of the number of enclosed particles in each selected area. Note that FLBs were
always predominantly found in the grey matter without prominent accumulations at any specific neuroanatomical site. (histograms: n = 3 per
group, mean + SD, * P <0.05, ** P <0.01, *** P <0.005; bar in b: 50 μm). d, day; FLBs, fluorescent latex beads; n, number; TA, tibialis anterior.
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(2,342, 1,122, and 1,180 μg/g of dry muscle tissue, re-
spectively). Al was additionally located in muscle and
distant tissues by PIXE [19]. Random scanning of 20 μm
thick sections, sampled and processed with careful protec-
tion against environmental Al, disclosed significant Al sig-
nals in muscle, spleen and brain (Figure 1b-c). In brain, Al
spots accounted for 38, 21, and 37% of 500 × 500 μm
tested fields at d21, and months 6 and 12 (mo6 and mo12)
post-injection, respectively (mean = 31.5%; n = 73 fields,
Figure 1d). The dip at month 6, was either due to inter-
individual variations in aluminum handling or to sampling
problems related to variable proportions of grey and white
matter in the randomly scanned areas (see below). The
spot size ranged from about 1 to 14 μm. By comparison,
five unvaccinated mice showed only seven positive out of
94 tested fields (mean = 7.4%). These results confirmed
that Al derived from alum can be translocated to, pene-
trate and persist in brain tissue [21-23]. Al depots detected
in spleen and brain could have resulted from either phy-
sical translocation of alum particles, or in situ aggregation
of soluble Al, or both.
Fluorospheres injected into mouse muscle undergo
lymphatic and systemic biodistribution
To examine if particles translocate to distant sites, we next
injected polychromatic FLBs. A size of 500 nm was chosen
as an approximation of the average size of alum agglome-
rates observed in vivo, allowing FLB visualization as indi-
vidual spheres by confocal and fluorescence microscopes
(resolution >200 nm). After i.m. injection of 20 μL
Figure 5 FLBs in various neural cells. a) Unstained section of the brain parenchyma of a CX3CR1GFP/+ mouse at d90 post-injection showing
individual FLBs in a significant proportion of GFP+ ramified microglial cells; b-e) In brain of C57 mice at d21post-injection, FLBs were detected in
F4/80+ perivascular macrophages (b), GFAP+ astrocytes (c), neurotraceW+ neurons (d), and vimentin+ pial cells (e); (bars: 10 μm). d, day; FLB,
fluorescent latex beads.
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suspensions, FLBs transiently peaked in free form in blood
(1,200 + 400 FLBs per 100 μL) at hour 1. As early as 1
hour post-injection, some FLBs had also reached DLNs. I.
m. injection of GFP+CD45+ cells, either pre-loaded with
FLBs or coinjected with FLBs, showed no GFP+ cells
translocation to DLNs at hour 1 (data not shown), indicat-
ing early cell-independent particle translocation to DLNs
by lymphatic drainage of the muscle interstitial fluid [24].
In DLNs, however, most FLBs were cell-associated
suggesting rapid capture by DLN resident cells. Within 24
hours, FLBs were phagocytosed by muscle CD11b+ MO/
MPs. Phagocytes progressively cleared the particles away
from the interstitium to form collections (Figure 2a),
mainly located in muscle envelopes at d4.
At d4, FLBs had dramatically increased in DLNs,
forming intracellular agglomerates in the interfollicular
area (Figure 2b-e). Particle-loaded cells extracted from
DLNs at d4 were CD45+, CD11b+, and more often
GR1+/Ly6C+ (69% to 81%), and CD11c+, with either
Table 1 Distribution of particles (percent of total)
according to post-injection time
Time post-injection D21 D90 D180 D365
Localization
Choroid plexus 0% 5% 5% 3%
Leptopmeninges 9% 5% 0% 3%
Parenchyma 91% 90% 95% 94%
Figure 6 Mechanisms of FLBs translocation. a) Compared to the i.m. route, direct injection of FLBs in the tail vein of C57 mice was associated
with almost no brain translocation at both d21 and d90 post-injection; b) Popliteal and inguinal DLN ablation was associated with a marked
decrease of FLB-loaded cells in blood, spleen and brain at d21 post-injection; c) The mdx mouse with altered BBB showed a marked increase of
the perivascular CD11b+ cell population, and significant angiogenesis assessed by an increase of CD31+ endothelial cells, compared to normal
C57 mice; d-e) Mdx mice showed increased incorporation of FLBs in brain; compared to C57 mice, mdx mice had increased FLB neurodelivery at
both d21 and d90, as assessed by both histology (d) or after CD11b+ cell sorting (e); f) At d21, FLBs were mainly detected outside capillary
basement membranes immunostained for collagenIV (upper panel), closely associated with CD11b+ perivascular macrophages (lower panel);
(histograms: n = 3 per group, mean + SD, * P <0.05, ** P <0.01, *** P <0.005; bar in d: 10 μm). d, day; DLN, draining lymph nodes; FLB, fluorescent
latex beads; n, number.
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intermediate (46%) or high (22%) intensity (Figure 2a,c,d),
thus corresponding to MO-derived inflammatory DCs
and MPs [25]. Co-injection of FLBs with the synthetic
prostaglandin analog BW245C, a compound known to in-
hibit DC migration [20], inhibited FLB translocation to
DLNs at d4 by 32% in the popliteal and 69% in the in-
guinal DLNs, respectively (Figure 2f). This indicated
prominent particle transport within phagocytic cells, at
least downstream to popliteal DLN. At later time points,
both the number of particle-loaded cells and the indivi-
dual cell load markedly decreased in DLNs (Figure 2e).
While decreasing in DLNs, FLBs dramatically increased
in spleen from d4 to d21 (Figure 3a,b). As spleen is un-
plugged to lymphatic vessels, the particle transfer from
DLNs to spleen implicated exit from the lymphatic system
through the thoracic duct and circulation in the blood
stream. Consistently, smears showed a similar d21 peak of
FLB-loaded CD11b+cells in the circulation (Figure 3c,d).
From d4, circulating FLBs were cell-associated (Figure 3d).
Most FLB-loaded cells in blood, DLNs and spleen exhibited
a few particles and were GR1+/Ly6C+ (Figure 3e,f). How-
ever, 22% to 33% were GR1-/Ly6C- in spleen and had
frequently incorporated >5FLBs, suggesting phagocytosis-
associated maturation of inflammatory MO-derived cells
[20,25,26]. FLB-loaded cells had markedly decreased in
spleen at d90. Although declining after d21, FLB-loaded
cells were still detected in blood at d45 and d90.
Fluorosphere incorporation into brain is delayed and
depends on prior cell loading in peripheral and lymphoid
tissues
Particles were detected in brain mainly from d21 post-
injection. After d21 post-i.m. injection, FLBs gradually
increased in brain until the d90 endpoint in the C57Bl6
mouse (Figure 4a,b) and until the d180 endpoint in the
CX3CR1GFP/+ mouse conventionally used to study resi-
dent microglia (Figures 4a and 5a). FLBs were predomin-
antly found in the grey matter (82% to 95%), regardless
of the amount of injected FLBs (4, 10, 20 μL), vaccine
co-injection (36 μL), or post-injection time from d21 to
d365. Some FLBs were detected in leptomeninges (9%)
and in the white matter (9%) at d21, but these locations
became rare at later time points. FLBs were <5% in chor-
oid plexus (Table 1). Comparative FLB distribution at
month 3, month 6 and month 12 showed no prominent
accumulations of particles at any neuroanatomical location
(Figure 4c). FLBs were usually detected in brain as single
particles located within or at the surface of cells; 37%
to 62% of particles could be reliably assigned to a given cell
subset by immunohistochemical screening. At d21,
Figure 7 GFP+ BM chimeric mice. a-c) Chimeric mice injected intramuscularly with FLBs showed GFP+ BM-derived cells enclosing FLBs among
inflammatory cells extracted from the injected muscle (a) at d4 after FLB injection, in spleen (b) and brain (c) at d33 after FLB injection.
d-e) Chimeric mice showed incorporation of GFP+ cells in the brain, mainly in the form of perivascular cells in the cortex (d) and, occasionally, in
more deeply located ramified CD11b+ cells (e, arrow) at d180 post-BM transplantation. (bars: 10 μm). BM, bone marrow; d, day; FLB, fluorescent
latex beads.
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particles were mainly associated with perivascular CD11b+
MPs, but at d90 they were also found in deep ramified
CX3CR1+microglia (Figure 5a). Particles were also detected
in GFAP+ astrocytes, MAP2+ or Neurotrace-stained neu-
rons, and vimentin+ leptomeningeal cells (Figure 5b-e),
and in NG2+ oligodendroglial progenitors/pericytes (not
shown). FLB incorporation into GFP+ resident ramified
microglia of CX3CR1GFP/+ mice increased by up to 26-fold
the d21 value at d180.
Importantly, compared to i.m. injection, the same FLB
amount injected in the tail vein resulted in virtually no
cerebral entry at d21 and d90 in C57Bl6 mice (Figure 6a).
Moreover, ablation of popliteal and inguinal DLNs before
FLB injection in TA muscle resulted in 60% to 80% reduc-
tion of FLB incorporation into blood, spleen and brain
compartments at d21 (Figure 6b). Thus, cell uptake in
muscle and DLNs, and subsequent cell traffic to blood
crucially contributed to delayed particle translocation to
Figure 8 Biodistribution of Al particles. a) Morin stain for aluminum shows rounded alum cytoplasmic agglomerates within muscle
macrophages after i.m. vaccine administration in C57 mouse; b) Morin stain confirms that phagocytosed Al-Rho nanohybrids are associated with
Al and form particles similar in size to alum agglomerates; c-e) Al-Rho nanohybrids show a time-dependent distribution in DLNs, spleen, and
brain strikingly similar to that of FLBs; f) Al-Rho injected by the s.c. route translocate to DLNs and spleen, as observed with the i.m. route;
g,h) Ly6C immunophenotyping of CD11b+ cells that have ingested Al-Rho: most are Gr1+/Ly6C+ both in DLNs at d4 (g) and spleen at d21
(h). (histograms: n = 3 per group, mean ± SD, * P <0.05, ** P <0.01, *** P <0.005; bar in a: 10 μm). d, day; DLN, draining lymph nodes; FLBs,
fluorescent latex beads; n, number.
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spleen and brain (Figure 6a-f). Consistently, by injecting
FLBs into the muscle of GFP+BM chimeric mice obtained
by transplanting GFP+BM-derived cells to irradiated syn-
genic C56Bl6 mice [15], we detected FLB-loaded GFP+cells
in these organs (Figure 7a,b,c) and observed delayed in-
corporation of donor-derived cells in brain (Figure 7d,e).
This BM transplantation model is known to be associ-
ated with irradiation-induced BBB alteration. Dystrophin-
deficient mdx mice also have chronically altered BBB [27].
As a corollary, compared to age-matched controls, they
show significantly more CD31+ brain capillaries, and a
dramatic increase of perivascular CD11b+ macrophages
(Figure 6c) at the expense of deep ramified microglia. FLB
injection in mdx mouse muscle resulted in increased brain
incorporation of particles at both d21 and d90, as assessed
by both histology and cytospins of CD45+/CD11b+cells
extracted from brain (Figure 6d,e,f). Thus, BBB alteration
and/or the associated inflammatory/angiogenic response
likely favors brain incorporation of circulating particle-
loaded cells.
Fluorescent nanohybrids coated with Al(OH)3 undergo
CCL2-dependent systemic scattering and brain
penetration
For confirmatory experiments we constructed fluorescent
particles mimicking alum. Rhodamine nanohybrids [28]
were covalently coated with a Al(OH)3 shell. As assessed
by the Morin stain for alumimum, these Al-Rho particles
were avidly phagocytosed after i.m. injection and formed
intracellular agglomerates similar in size to the vaccine
adjuvant (Figure 8a,b). Biodistribution of the alum fluores-
cent surrogate injected into TA muscle was strikingly
similar to that of FLB (Table 2), including d4 peak in
DLNs, d21 peak in spleen, delayed entry in brain, and
main association with GR1+/Ly6C+ MOs in tissues
(Figure 8c-h). Compared to i.m. injection, s.c. injec-
tion of Al-Rho particles was associated with an even
higher rate of diffusion to DLNs (Figure 8f ), a find-
ing consistent with the presence of abundant migra-
tory DCs in skin.
On the grounds of a human SNP study, we performed
CCL2 gain and loss of function experiments to investigate
the role of CCL2-responsive cells in particle scattering
and neurodelivery. Injection of Al-Rho particles into the
TA muscle of CCL2-deficient mice decreased particle
incorporation by 35% into popliteal DLN and by 76%
in inguinal DLN at d4, and by 71%, 85% and 82% in
spleen, blood, and brain, respectively, at d21 (Figure 9a).
Conversely, Al-Rho particle biodistribution increased in dif-
ferent gain of CCL2 function experiments (Figure 9b-d).
I.m. co-injection of Al-Rho with murine recombinant
CCL2 (rCCL2: 1 μg) increased particle incorporation
by 47% into popliteal and 163% into inguinal DLN (d4),
and by 180% in spleen, 274% in blood, and 341% in
brain (d21).
Morever, slow intracerebral (i.c.) infusion of CCL2 by an
osmotic pump (180 pg/day during 15 days starting at d7
after Al-Rho i.m. injection) increased particle incorpor-
ation into brain by 74% at d21 compared to PBS control.
The combination of i.m. injection and i.c. infusion of
rCCL2 increased particle incorporation into the brain by
539%. Despite important interindividual variations, a con-
sistent trend of CCL2-dependent increase of Al brain
levels was detected 21 days after i.m. injection of 40 μL of
alum-containing vaccine (Figure 9e). Taken together these
results indicate that after i.m. injection, particles associ-
ated with inflammatory MOs can enter the brain using a
CCL2-dependent mechanism, possibly through a Trojan
horse mechanism. Importantly, Al-Rho particles gaining
access to the brain after i.m. injection remained intact
since they were still coated with Al(OH)3 as assessed by
both Morin stain (Figure 10a), and PIXE (Figure 10b).
Their incorporation in neural cells was consistently associ-
ated with the expression of IL-1β (Figure 10c), a reliable
marker of particle-induced NALP3 inflammasome activa-
tion [29].
Fluorescent nanohybrids coated with Al(OH)3 are retained
in brain
An apparently irreversible accumulation of nanomaterials
after i.m. injection was unique to brain tissue which lacks
conventional lymphatic pathways and may retain immune
cells [30]. We stereotactically injected 0.5 μL Al-Rho in
the striatum of C57Bl6 mice, and counted particles in cer-
vical LNs, blood, and spleen at d4 and d21. Compared to
the same amount of Al-Rho injected in the TA muscle, i.c.
injection was associated with almost no particle transloca-
tion to regional DLNs (Figure 10d), and the appearance of
eight-fold fewer particles in spleen (Figure 10e). Since 25
free Al-Rho particles per 100 μL were detected in blood at
hour 1, it is likely that the rare particles subsequently
detected in spleen reflected direct particle passage into
Table 2 Time of peak observation and peak value of particle loaded cells in studied organs (total number ± SD)
Particle Popliteal DLN Inguinal DLN Spleen Blood Brain
Peak Number of
loaded cells
Peak Number of
loaded cells
Peak Number of
loaded cells
Peak Number of
loaded cells
Endpoint Number of
loaded cells
FLB D4 21,117 ±1,235 D4 23,746±2,880 D21 76,503±11,850 D21 9,878±792 D90 577±96
Al-Rho D4 4,462 ± 257 D4 6,253±745 D21 27,570±6,670 D21 7,546±1,034 D90 613±137
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blood during i.c. injection. It seems, therefore, that lack of
recirculation likely contributed to progressive cerebral
particle accumulation.
Discussion
Particles injected by the i.m. or s.c. route gained access to
distant tissues. Latex and Al-Rho particles showed closely
similar biodistribution, suggesting a shared basic scatter-
ing mechanism. Initial cell uptake in peripheral and DLN
tissues and subsequent transport within inflammatory
MO-derived cells was critically involved, as indicated by
immunophenotyping, cell migration blockade and DLN
ablation. Cells were heavily loaded with particles soon
after i.m. injection but usually contained only one to two
particles after d4 and downstream the popliteal DLN,
pointing to either dilution by cell division [31] or particle
dispatching to other cells [32] within DLNs. Previous
studies have reported particle cell transport from skin
to DLNs [25] but downstream particle fate remained
largely unexplored [33]. There is strong evidence that,
Figure 9 CCL2-dependent systemic translocation of Al-particles. a) CCL2 deficient mice show a dramatic decrease of Al-Rho translocation
from the injected muscle to inguinal DLN, blood, spleen and brain, as compared to their respective controls (100%). Note that the difference is
significant but less pronounced for popliteal DLN; b) rCCL-2 co-injection with Al-Rho is associated with a marked increase of Al-Rho translocation
from the injected muscle to inguinal DLN, blood, spleen and brain, compared to their respective controls (100%). Note that the difference is
significant but less pronounced for popliteal DLN; c) rCCL-2 infused by an osmotic micropump into the striatum for 15 days is associated with a
significant increase of Al-Rho translocation from the injected muscle to brain; d) Combined i.m. and i.c. injection of rCCL2 is associated with a
dramatic increase of FLB translocation from muscle to both blood and brain; e) Alum-containing vaccine injected into muscle of CCL-2-deficient,
normal, and rCCL-2 mice was associated with a trend of CCL-2-dependent increase of Al concentration levels in brain; (histograms: n = 3 per
group, mean ± SD, * P <0.05, ** P <0.01, *** P <0.005, except [e]: n = 10 per group, mean ± SEM). Al-Rho, Al(OH)3 rhodamine nanohybrid; DLN,
draining lymph nodes; FLB, fluorescent latex beads; n, number; SEM, standard error of the mean.
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in inflammatory conditions, all DCs reaching DLNs
do not die locally but may rather gain access to the
blood through efferent lymphatics and the thoracic
duct, and present antigens in spleen and bone marrow
[33]. Ingested adjuvant particles boost this phenomenon
which in turn likely favors their translocation from
the injection point to distant sites as: (i) alum induces
rapid differentiation of monocyte-lineage cells into
APCs [34] and stimulates their migration to DLNs [35],
(ii) beryllium hydroxide, a closely similar particulate
adjuvant, strongly stimulates DC egress through effer-
ent lymphatics [36]; and, as shown herein, (iii) Al de-
posits may be detected by PIXE in spleen and brain
after i.m. injection of alum.
Delayed and slowly progressive particle accumulation
occurred in intact brains. Experiments using the parabi-
osis model [37] or avoiding brain irradiation prior to BM
transplantation [38] have shown that endogenous micro-
glia are not replenished by the periphery under normal
central nervous system (CNS) conditions. Although low
chimerism inherent in these experimental approaches
may lead to some underestimation of slow microglia turn-
over from the periphery [39], a more likely explanation of
our findings is that particles exert stimulatory effects on
myeloid cell trafficking [36]. Both latex particles and
aluminum hydroxide agglomerates promote inflammation
[40,41] and non-specific immune stimulation can increase
monocyte transendothelial migration by up to 20-fold in
in vitro models of the BBB [42]. Consistently, i.m. injec-
tion of rCCL2 strongly increased particle incorporation
into intact brain while CCL2-deficient mice had decreased
neurodelivery. rCCL2 likely induced the exit of inflamma-
tory MOs and hematopoietic stem and progenitor cells
from BM [43], followed by their transmigration to the
injected muscle and to DLNs [44], prior to particle loading
and dissemination. Cerebral infusion of low doses of
rCCL2, mimicking pathological states attracting inflam-
matory monocytes, also increased particle neurodelivery.
Figure 10 Al-Rho particles remain in brain and may induce inflammation. a) Al-Rho nanomaterial detected in brain by rhodamine
fluorescence (upper row and emission spectrum at 560 nm) remains associated with Al as assessed by Morin stain (middle row and emission
spectrum at 520 nm); b) Al-Rho nanomaterial detected in the brain by PIXE. Al coating colocalizing with Gd core assesses the integrity of Al-Rho
nanohybrid after translocation; c) In mice with i.m. co-injection of Al-Rho and rCCL-2, particle incorporation into neural cells was associated with
immunohistochemical expression of IL1beta; d) Stereotactic injection of Al-Rho into the striatum was associated with no translocation to cervical
LNs (CLN) at d4, contrasting with conspicuous translocation to popliteal LNs (PLN) observed when the same particle amount was injected in TA
muscle; e) Stereotactic injection of Al-Rho into the striatum, compared to similar injection into muscle, was associated with very little
translocation to spleen at both d4 and d21. (histograms: n = 3 per group, mean ± SD, * P <0.05, ** P <0.01, *** P <0.005; bar in c: 10 μm). Al(OH)3
rhodamine nanohybrid; d, day; LN, lymph nodes; n, number; PIXE, particle induced X-ray emission;TA, tibialis anterior.
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Intracerebral particles translocated with time from peri-
vascular macrophages to the sentinel network of paren-
chymal microglia and to other resident neural cells and
likely failed to recirculate, thus explaining their progres-
sive cerebral accumulation.
Conclusions
Taken together, our results indicate that, similarly to intra-
cellular bacteria [45], nanomaterials can be transported by
MO-lineage cells to DLNs, blood and spleen, and, simi-
larly to HIV [46] and other pathogens [47], may use
CCL2-dependent MO transmigration across the BBB to
enter the brain. This occurs at an extremely low rate in
normal mice, the percentage of injected particles found
in tissues being estimated at 1:105 in d21 spleen and 1:107
in d90 brain, consistent with the excellent tolerance of al-
most all individuals to limited doses of alum and other
injected particles. Neurodelivery of nanomaterials signifi-
cantly increased in mice with either a weak BBB or high
tissue levels of CCL2, as previously suspected for patho-
gens in humans [48]. On the one hand, such a cerebral in-
corporation of nanomaterials injected into tissues should
be regarded as an interesting characteristic in the setting
of therapeutic strategies targeting the CNS. On the other
hand, alum has high neurotoxic potential [49], and plan-
ning administration of continuously escalating doses of
this poorly biodegradable adjuvant in the population
should be carefully evaluated by regulatory agencies since
the compound may be insidiously unsafe. It is likely that
good tolerance to alum may be challenged by a variety of
factors including overimmunization, BBB immaturity, in-
dividual susceptibility factors, and aging that may be asso-
ciated with both subtle BBB alterations and a progressive
increase of CCL2 production [50].
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